The ADAS-Cog test demonstrated significant cognitive improvements with both of the Mindrevive™ doses compared to placebo after 12 weeks. Intragroup analysis showed more pronounced and rapid ...
Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort move toward normal aging profiles across validated clinical scales, supporting its relevance in early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results